https://www.youtube.com/watch?v=S_YMGmHqIW4 This video from Claire Blatt shares a lecture about the effects of two blood-clotting disorders: hemophilia A and hemophilia B. MORE: A study shows that NovoSeven counters bleeding in children with hemophilia. Though the lecture is aimed at nurses, it’s helpful for anyone looking to learn about these…
Search results for:
Hemophilia is an inherited blood-clotting disorder primarily affecting males, with no known cure, though it can be managed with medication and lifestyle adjustments. Patients are encouraged to exercise for joint and muscle health but should avoid contact sports. Kovaltry (octocog alfa) is a safe and effective preventive treatment for hemophilia A in both children and adults. Bayer is also developing BAY94-9027, a long-acting Factor VIII therapy for hemophilia A, designed for less frequent dosing.
AI-generated summaries are for informational use only, based on content from multiple pages. They may not reflect full context. For complete details, see the original sources. Consult a qualified healthcare professional for medical advice.
Kovaltry (octocog alfa) is effective and safe as a preventive treatment for children with hemophilia A, a European real-world study reports. The study, “Real-world evidence on Kovaltry (81-8973) in children with moderate or severe hemophilia A in Europe: a…
Bayer has filled a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) requesting marketing approval for its long-acting human Factor VIII therapy, BAY94-9027, to treat hemophilia A. The therapy is designed to allow for dosing at intervals as long as once every seven days. The…
Preventive treatment with Kovaltry (octocog alfa) is safe and effective at preventing bleeds, including joint bleeds, for up to two years in people with hemophilia A, a long-term extension study shows. Findings were reported in the study “BAY 81-8973 demonstrated efficacy, safety and joint status improvement…
Preliminary results from the U.S. part of Bayer’s global HemACTIVE patient survey show that a majority of hemophilia patients want to be more active but are limited in their capacity to perform outdoor activities. The data was shared by Bayer at the World Federation of Hemophilia 2018…
Preventive treatment with Hemlibra (emicizumab) improves health-related quality of life (HQRoL) in children with hemophilia A who develop inhibitors, or neutralizing antibodies, against engineered factor VIII (FVIII), an essential blood-clotting protein, a new analysis of a Phase 3 trial shows. Such Hemlibra therapy also reduces the burden on…
A new five-year alliance between Bayer and the World Federation of Hemophilia (WFH) Humanitarian Aid Program will deliver training, education and treatments to healthcare professionals in more than 60 underserved countries. ”Three out of four people with bleeding disorders living in developing countries do not have access to…
Jivi (BAY94-9027), a lab-made version of the blood clotting factor VIII (FVIII), has been approved by the European Commission for the prophylactic (preventative) treatment of hemophilia A in patients older than 12, Bayer announced. The recommended prophylaxis for Jivi administration is every five days, every…
In 2025, Hemophilia News Today delivered readers timely reporting on research, therapeutic options, and clinical trials for hemophilia. Below is a list of the top five most-read stories we published this year. As we enter 2026, we look forward to continuing to support and serve as a source…